|
Overall (N=387)
|
Sex (Male)
|
261 (67.4%)
|
Age at procedure
|
|
Median (Q1, Q3)
|
68.0 (60.0, 74.0)
|
Range
|
27.0 - 87.0
|
Hypertension
|
280 (72.4%)
|
Diabetes Mellitus (Type II)
|
47 (12.1%)
|
Coronary artery disease
|
74 (19.1%)
|
Congestive heart failure
|
152 (39.3%)
|
Dyslipidemia
|
244 (63.0%)
|
Thyroid status
|
|
Amiodarone Induced Hyper
|
1 (0.3%)
|
Hyper
|
2 (0.5%)
|
Hypo
|
63 (16.3%)
|
None
|
317 (81.9%)
|
Subclinical Hypo
|
4 (1.0%)
|
Obstructive sleep apnea
|
185 (47.8%)
|
Chronic obstructive pulmonary disease
|
40 (10.3%)
|
Chronic kidney disease
|
78 (20.2%)
|
Pre-procedure creatinine
|
|
Median (Q1, Q3)
|
1.1 (0.9, 1.2)
|
Range
|
0.6 - 4.9
|
Atrial fibrillation/flutter status
|
|
History of atrial fibrillation/flutter without intervention
|
89 (23.0%)
|
No history of atrial fibrillation/flutter
|
42 (10.9%)
|
Previous ablation for atrial fibrillation/flutter
|
256 (66.1%)
|
Congenital heart disease
|
25 (6.5%)
|
Valve repair/replacement
|
59 (15.2%)
|
MAZE
|
30 (7.8%)
|
VT11Ventricular tachycardia/PVC22Premature ventricular contraction ablation
|
6 (1.6%)
|
AVNRT33Atrioventricular nodal reentrant tachycardia ablation
|
5 (1.3%)
|
HOCM44Hypertrophic obstructive cardiomyopathy s/p myectomy
|
12 (3.1%)
|
WPW55Wolff-Parkinson-White ablation
|
1 (0.3%)
|
Other cardiac symptoms
|
1 (0.3%)
|
Ablation success
|
323 (83.5%)
|
Acute termination
|
324 (83.7%)
|
Lack of inducibility
|
385 (99.5%)
|
Use of DCCV66Direct current cardioversion during procedure
|
|
None
|
322 (83.2%)
|
Hemodynamic Instability
|
2 (0.5%)
|
Failure of termination
|
63 (16.3%)
|